drugset

drugset / Trial / NCT05451615

Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis

NCT05451615 ↗

Phase 3 Unknown 90 enrolled Zhejiang Provincial People's Hospital

RandomizedSingle-groupOpen-labelTreatment

Summary

The aim of this study is to observe the clinical efficacy and safety of abatacept combined with JAK inhibitor in the treatment of D2TRA patients

Timeline

Start: 2022-09-30
Primary completion: 2023-06-30
Completion: 2024-06-30

Publications

Background Iglesias M, Khalifian S, Oh BC, Zhang Y, Miller D, Beck S, Brandacher G, Raimondi G. A short course of tofacitinib sustains the immunoregulatory effect of CTLA4-Ig in the presence of inflammatory cytokines and promotes long-term survival of murine cardiac allografts. Am J Transplant. 2021 Aug;21(8):2675-2687. doi: 10.1111/ajt.16456. Epub 2021 Feb 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abatacept	Other / unclassified	0 unknown	—

Indications